Viral Vector Service Market Report 2026

The viral vector service market size has grown exponentially in recent years. It will grow from $2.53 billion in 2025 to $3.14 billion in 2026 at a compound annual growth rate (CAGR) of 24.2%. The growth in the historic period can be attributed to increasing use of viral vectors in biomedical research, expansion of gene delivery applications, early adoption of outsourced vector services, growth of translational medicine programs, availability of standardized production protocols.

The viral vector service market size is expected to see exponential growth in the next few years. It will grow to $7.41 billion in 2030 at a compound annual growth rate (CAGR) of 23.9%. The growth in the forecast period can be attributed to increasing commercialization of gene-based therapies, rising demand for customized vector solutions, expansion of contract service partnerships, growing regulatory requirements for viral vectors, increasing investment in advanced vector technologies. Major trends in the forecast period include increasing demand for end-to-end viral vector services, rising adoption of integrated development and manufacturing models, growing focus on quality-controlled vector production, expansion of custom vector design capabilities, enhanced emphasis on regulatory compliance services.

The increasing prevalence of infectious diseases is expected to drive the growth of the viral vector services market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, which can be transmitted directly or indirectly between individuals. The incidence of these diseases is rising due to increased travel, which facilitates the rapid spread of pathogens across regions. Viral vector services aid infectious disease management by providing reliable platforms for the development of vaccines and gene-based therapeutics. They allow efficient delivery of genetic material to target cells, accelerating the creation of effective treatments and improving public health responses. For example, in February 2024, the UK Health Security Agency, a UK-based government organization, reported that tuberculosis cases in England reached 4,850 in 2023, a 10.7% increase from 4,380 cases in 2022. Consequently, the rising prevalence of infectious diseases is fueling the viral vector services market.

Key players in the viral vector services market are emphasizing innovation in lentiviral vector design and production, such as fourth-generation vector systems, to improve payload capacity, potency, and safety while streamlining complex gene therapy development. Fourth-generation vector systems are advanced lentiviral delivery technologies with enhanced safety profiles, optimized gene packaging, and modular components that support scalable, plug-and-play manufacturing for cell and gene therapies. For instance, in May 2023, Oxford Biomedica plc, a UK-based viral vector contract development and manufacturing organization (CDMO), launched the TetraVecta system. This system enhances vector quality, potency, and packaging efficiency while incorporating advanced safety features. It enables the creation of high-titer, stable producer cell lines, supporting scalable in vivo gene therapy development, streamlining manufacturing, and reducing production timelines for gene therapy programs.

In October 2025, Oxford Biomedica plc, a UK-based cell and gene therapy CDMO, acquired RTP Operating LLC for $4.5 million (£3.4 million). This acquisition expands Oxford Biomedica’s commercial-scale viral vector manufacturing capabilities in the United States, strengthening its end-to-end CDMO services, increasing good manufacturing practice (GMP) capacity, and supporting clinical and commercial gene therapy programs for both existing and new clients. RTP Operating LLC is a US-based biopharmaceutical company providing a commercial-scale viral vector manufacturing facility.

Major companies operating in the viral vector service market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, FUJIFILM Diosynth Biotechnologies, Danaher Corporation, Sartorius AG, Charles River Laboratories Inc., Takara Bio Inc., Oxford Biomedica plc, ProBioGen AG, NorthX Biologics Ltd., PackGene Biotech Ltd., Ascend Advanced Therapies Ltd., VectorBuilder Inc., ViroCell Biologics Ltd., Genezen Ltd., Scorpius BioManufacturing Ltd., VGXI Inc., Creative Biogene Ltd., ReiThera Ltd., Tailored Genes Ltd., CoJourney Ltd., InnovaVector Ltd.

North America was the largest region in the viral vector service market in 2025. The regions covered in the viral vector service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral vector service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the viral vector service market by increasing costs of imported bioreactors, analytical instruments, plasmid materials, and downstream processing equipment required for vector design and production. North America and Europe are most affected due to reliance on imported high-precision bioprocessing tools, while Asia-Pacific faces increased costs for expanding service infrastructure. These tariffs are raising service pricing and extending project timelines for clients. However, they are also encouraging domestic capability building, localized service expansion, and investment in regionally sourced bioprocess technologies to support long-term market growth.

The viral vector service market research report is one of a series of new reports that provides viral vector service market statistics, including viral vector service industry global market size, regional shares, competitors with a viral vector service market share, detailed viral vector service market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector service industry. This viral vector service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral vector service involves the design, production, and validation of viral vectors for gene delivery in research and therapeutic applications. These services facilitate the safe and efficient transfer of genetic material into target cells, supporting the development of advanced biologics and gene therapies. They ensure high-quality vector production through standardized protocols and adherence to regulatory requirements.

The main service types of viral vector services include process development, manufacturing, quality control, and others. Process development focuses on the systematic design, optimization, and scaling of production processes to ensure efficiency, reproducibility, and compliance with quality standards. These services cover various vector types, including adenoviral vectors, lentiviral vectors, adeno-associated viral (AAV) vectors, retroviral vectors, and more. Applications include gene therapy, vaccinology, oncology, and other fields, serving end users such as pharmaceutical and biotechnology companies, research institutes, and others.

The viral vector service market includes revenues earned by entities through vector design, process development, analytical testing, scale-up production, quality control, regulatory support, purification, and fill and finish. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.